Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population

Almoguera, B.; Lopez-Castroman, J.; Riveiro-Alvarez, R.; Dorado, P.; Vaquero-Lorenzo, C.; Fernandez-Piqueras, J.; Llerena, A.; Abad-Santos, F.; Baca-Garcia, Enrique; Dal-Re, R.; Ayuso, C.; Spanish Consortium of Pharmacogenetics Research in Schizophrenia

Risperidone non-compliance is often high due to undesirable side effects, whose development is in part genetically determined. Studies with genetic variants involved in the pharmacokinetics and pharmacodynamics of risperidone have yielded inconsistent results. Thus, the aim of this study was to investigate the putative association of genetic markers with the occurrence of four frequently observed adverse events secondary to risperidone treatment: sleepiness, weight gain, extrapyramidal symptoms and sexual adverse events. A series of 111 schizophrenia inpatients were genotyped for genetic variants previously associated with or potentially involved in risperidone response. Presence of adverse events was the main variable and potential confounding factors were considered. Allele 16Gly of ADRB2 was significantly associated with a higher risk of sexual adverse events. There were other non-significant trends for DRD3 9Gly and SLC6A4 S alleles. Our results, although preliminary, provide new candidate variants of potential use in risperidone safety prediction.


Also Published In

The Pharmacogenomics Journal

More About This Work

Academic Units
Published Here
July 11, 2013